EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Danaher Corporation (DAP) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Danaher Corporation €163, price €191, upside -14.6%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · DE · ISIN US2358511028

DC Broad data Sep 28, 2026

Danaher Corporation

DAP · XETRA

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value €163.42 · Overvalued (−14.6%)
✓Quality 71/100
!Weak Growth (revenue 5y +2.0 %/yr)
✓Solidly profitable · 14.9% net margin (TTM)
✓Low debt · generates free cash flow
✓0.7% dividend yield · Well covered
!Moderate moat 56/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€257.20 €139.81 Fair Value €163.42 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range €139.81 – €257.20 · fair‑value band €114.22 – €212.82 · the €191.35 price screens above the €163.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.

Show more

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Stock analysis

Danaher Corporation (DAP) currently trades at €191.35, while our model-based Fair Value estimate is €163.42, 14.6% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of €100.85 per share, and 0 of the 26 models we run sit above the €191.35 price.

Bear case: the Dividend Discount group reads lowest at €17.74, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: €114.22 (bear) to €212.82 (bull), the price of €191.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Danaher Corporation reported revenue of $24.6B in FY2025 versus $29.5B in FY2021, a compound −4.4%/yr. Reported net income was $3.6B in FY2025, compounding −13.4%/yr from FY2021.

Key figures

Market cap €137B · P/E ratio 42.1 · P/S ratio 6.20 · EPS (TTM) €4.54 · Dividend yield 0.7% · Net margin 14.7% · Return on equity 7.1% · Return on assets (EBIT) 7.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, DAP screens richer than that median.

Fair Value models

Bear €114.22 Fair Value €163.42 Bull €212.82
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€2.40 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF €64.38 €117.06 €201.44 78
Growth DCF €65.07 €116.52 €198.54 76
Residual Income €53.31 €55.78 €61.52 76
All 26 models by family
DCF Models
FCF DCF €64.38 €117.06 €201.44 78
Owner Earnings €59.30 €108.69 €187.81 74
5Y Revenue Exit €44.54 €80.66 €127.16 71
5Y EBITDA Exit €66.42 €123.08 €190.78 73
5Y P/E Exit €54.96 €100.85 €150.28 69
10Y Revenue Exit €49.09 €84.48 €133.34 65
10Y EBITDA Exit €64.94 €114.51 €183.57 67
10Y P/E Exit €57.53 €98.77 €151.60 63
Earnings-Based
Graham-Dodd €30.85 €113.10 €152.69 64
Lynch FV €26.99 €38.56 €50.12 61
PEG = 1.0 €26.99 €38.56 €50.12 57
EPV €31.18 €39.26 €46.33 74
Dividend Discount
Gordon GGM €10.12 €21.04 €33.38 66
DDM Multi-Stage €10.12 €17.74 €22.08 66
Multiples
P/E Multiple €74.85 €99.79 €124.74 63
P/S Multiple €57.84 €77.11 €96.39 58
P/B Multiple €57.84 €77.11 €96.39 55
EV/EBIT €57.73 €82.75 €107.77 65
EV/EBITDA €76.74 €108.09 €139.44 67
EV/Revenue €36.25 €59.21 €82.16 52
Asset-Based
NCAV (Graham) €32.97 €44.18 €65.94 54
Growth DCF
Growth DCF €65.07 €116.52 €198.54 76
Rev-Margin DCF €44.54 €80.80 €124.57 71
Economic Profit
Residual Income €53.31 €55.78 €61.52 76
ROIC Compounder €31.18 €39.26 €46.33 72
Growth Earnings
Growth-Adj P/E €52.13 €74.47 €96.80 67

Open the full fair value analysis →

Notify me when DAP reaches fair value

Put DAP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 71/100

Of which business quality 70 · Market factors (momentum, volatility) 58

Profitability 36
Margins and returns on capital today
Quality Growth 37
Are margins and returns improving?
Cashflow 85
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 51
Price trend over the last 3–12 months (market factor)
52W Momentum 58
Distance to the 52-week high (market factor)
Net Issuance 96
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2020 (pandemic). Over 10 years: +1.8% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+0.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.1%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.1% vs 3.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 19%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.4% a year for the price and +4.8% for the forecasts.
Forecast 2026 (sales)+6.1%
Forecast 2027 (sales)+8.9%
Projected 2028 (sales)+8.0%
Projected 2029 (sales)+7.2%
Projected 2030 (sales)+6.3%

DAP screens overvalued: fair value 15% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Danaher Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%
Quest Diagnostics Incorporated DGX $237.62 $171.69 −28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Danaher Corporation · Fair Value
€163.42 −15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Danaher Corporation Fair Value". https://www.fairvalue-calculator.com/stock/DAP

Frequently asked questions

Is Danaher Corporation (DAP) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of €163.42 versus a price of €191.35, about −15% upside (overvalued).
What is the fair value of DAP?
Our model-based fair value for Danaher Corporation is €163.42 (as of Sep 28, 2026), built from audited fundamentals. The current price: €191.35.
What is the quality score of DAP?
Danaher Corporation has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Danaher Corporation (DAP)?
Our model-based price target is the fair value of €163.42 (as of Sep 28, 2026) from 26 valuation models. Cautious scenario €114.22, optimistic scenario €212.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Danaher Corporation stock forecast for 2026?
Our models put fair value at €163.42, about −15% upside versus a price of €191.35 (overvalued). Cautious scenario €114.22, optimistic scenario €212.82. The calculation is refreshed regularly with new filings.
What is the revenue of Danaher Corporation (DAP)?
Danaher Corporation reported trailing-twelve-month revenue of about $24.8B (latest available figure, as of Sep 28, 2026).
Does Danaher Corporation pay a dividend?
Danaher Corporation currently shows a dividend yield of about 0.71% relative to its recent price (as of Sep 28, 2026).
What growth is priced into Danaher Corporation (DAP)?
For today's price to be fair in a discounted-cash-flow model, Danaher Corporation would have to grow free cash flow by +15.1 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. As of Sep 28, 2026.
What discount rate (WACC) does the fair value of DAP use?
Our models discount Danaher Corporation at 8.6 %: a base by market capitalisation (large), damped by beta 0.82, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Danaher Corporation that is +15.1 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Danaher Corporation (DAP) delivered so far?
Over the past 5 years revenue at Danaher Corporation grew +2.0 % a year. The price currently implies +15.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Danaher Corporation (DAP) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Danaher Corporation (+15.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Danaher Corporation (DAP)?
The free-cash-flow yield on the price is 3.40 %: that much free cash flow Danaher Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Danaher Corporation (DAP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Danaher Corporation it is €163.42 per share (as of Sep 28, 2026), against a price of €191.35. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Danaher Corporation stock overvalued or undervalued in 2026?
As of Sep 28, 2026, DAP trades above its calculated fair value: price €191.35, fair value €163.42, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DAP?
No. The price is what the market pays today (€191.35); the fair value is what the company's own numbers justify (€163.42). For Danaher Corporation the two are €27.93 per share apart. That gap is exactly why we show both numbers side by side.
How much is Danaher Corporation worth?
The market values Danaher Corporation at about €137B (market capitalisation, as of Sep 28, 2026). Per share that is €191.35; our models calculate a fair value of €163.42 per share.
What do the bullish and bearish scenarios say about DAP?
Our models span a range for Danaher Corporation: cautious scenario €114.22, base €163.42, optimistic €212.82 per share (as of Sep 28, 2026, price €191.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is DAP from its 52-week high?
Danaher Corporation trades at €191.35, about 7% below its 52-week high of €205.73 and 37% above the low of €139.81 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €163.42 is for.
Which stocks are comparable to Danaher Corporation?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, WuXi AppTec Co, Agilent Technologies, Inc, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Danaher Corporation stock attractive at the current price?
The data as of Sep 28, 2026: price €191.35, calculated fair value €163.42 (−15%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DAP calculated?
We run Danaher Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €163.42, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Danaher Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Danaher Corporation (DAP)?
The closing price on Oct 2, 2026 was €191.35. Our model-based fair value is €163.42, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Danaher Corporation right now?
A fairly wide model range (€114.22 to €212.82) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Danaher Corporation (DAP) come from?
Earnings per share at Danaher Corporation grew +3.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.2 %, EBIT margin +2.2 %, tax rate +0.6 %, residual (interest, one-offs) −1.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Danaher Corporation

How large is the market capitalisation of Danaher Corporation (DAP)?
The market capitalisation of Danaher Corporation is €137B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Danaher Corporation (DAP)?
The price-to-earnings ratio of Danaher Corporation is 42.1. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Danaher Corporation (DAP)?
The price-to-sales ratio of Danaher Corporation is 6.20 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Danaher Corporation (DAP)?
Earnings per share at Danaher Corporation are €4.54 (price ÷ EPS = P/E 42.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Danaher Corporation (DAP)?
The dividend yield of Danaher Corporation is 0.7% (payout 30.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Danaher Corporation (DAP)?
The net margin of Danaher Corporation is 14.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Danaher Corporation (DAP)?
The return on equity (ROE) of Danaher Corporation is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Danaher Corporation (DAP)?
On an EBIT basis the return on assets of Danaher Corporation is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Danaher Corporation (DAP)?
The operating margin of Danaher Corporation is 22.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Danaher Corporation (DAP)?
Revenue at Danaher Corporation is growing +3.7% versus a year earlier (3y avg −7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Danaher Corporation (DAP)?
Earnings per share at Danaher Corporation are growing +9.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Danaher Corporation (DAP) carry?
The net debt of Danaher Corporation is $13.8B (fiscal year 2025, ≈ 2.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.